A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech ...

Metsera and Maze Therapeutics priced their Nasdaq IPOs, raising $275M and $140M respectively. Both companies backed by ARCH ...

The IPO comes amid a deregulatory push in the energy sector by President Donald Trump, who repeated the "drill, baby, drill" slogan in his inaugural address. Earlier this week, Sean Duffy, the newly ...

Shares of Maze Therapeutics rose nearly 1% in their Nasdaq debut on Friday, valuing the kidney disease drug developer at $690.37 million.

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

A registration statement on Form S-1 (File No. 333-284225) relating to the offering has been filed with the Securities and Exchange Commission and became effective on January 30, 2025. The offering is ...

Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain ...

Investors clamouring for exposure to US technology firms drove structured products volumes to record heights in 2024, underlining how the tech and AI frenzy has permeated the complex ecosystem ...